University of Pittsburgh, Tuskegee University and The University of North Carolina (UNC) researchers have developed a cocktail of chemokine peptides, a class of signaling molecules, to reduce fibrosis. This novel therapeutic approach regulates key biological pathways implicated in fibrosis. Unlike many existing treatments which address the symptoms of fibrosis, this treatment strategy targets the underlying causes of the disease. The resulting positive outcomes could include prevention of long-term health complications and a decrease in early mortality.